Jakarta, August 28, 2025 – PT Etana Biotechnologies Indonesia (Etana) has officially been designated as one of the Centers of Excellence for Vaccine and Biotechnology Development by the Ministry of Health of the Republic of Indonesia. The designation is stated in the Decree of the Director General of Pharmaceuticals and Medical Devices No. HK.02.02/E/1504/2025.
Read MoreJakarta, July 14, 2025 – PT Etana Biotechnologies Indonesia (Etana), a national biopharmaceutical company focused on developing treatments for metabolic and chronic diseases, has signed a collaboration agreement with Universitas Indonesia Hospital (RSUI) to conduct clinical research on therapy for Type 2 Diabetes Mellitus.
Read MoreJakarta, June 12, 2025 – Etana Biotechnologies Indonesia (Etana) has officially entered into a partnership with the Faculty of Military Pharmacy of University of Defense (Unhan) to strengthen collaboration in education, research, and community service.
Read MoreJakarta, May 19, 2025 – PT Etana Biotechnologies Indonesia (Etana) confirmed its dedication to helping Indonesia become self-sufficient in pharmaceuticals by getting approval for Clinical Trials (PPUK) and a Marketing Authorization Number (NIE) from the Indonesian Food and Drug Authority (BPOM RI) for two important products.
Read MoreBogor, April 30, 2025 – In commemoration of World Immunization Week 2025, PT Etana Biotechnologies Indonesia (Etana), in collaboration with the Bogor City Government, conducted a vaccination program for children. A total of 2.081 doses of Hepatitis A and PCV13 vaccines were administered during a series of events held at Bogor City Hall, Boxies Mall, and several schools across the city.
Read MoreJakarta, April 12, 2025 - PT Etana Biotechnologies Indonesia (Etana) introduced two new products in collaboration with global partner BeiGene (tislelizumab) and BRUKINSA® (zanubrutinib) during the Etana Oncology Summit, which also served as a scientific forum to discuss the latest advancements in cancer therapies.
Read More
